Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
0.15
Industry P/E
--
Debt to Equity
0.08
ROE
-0.62 %
ROCE
-58.08 %
Div. Yield
0 %
Book Value
2.34
EPS
-1.99
CFO
$-249.20 Mln
EBITDA
$-308.40 Mln
Net Profit
$-306.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NextCure Inc (NXTC)
| -40.34 | -24.47 | -44.11 | -68.06 | -53.85 | -58.31 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
NextCure Inc (NXTC)
| -32.15 | -19.15 | -76.50 | -44.95 | -80.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that... is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Address: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 Read more
Co-Founder, CEO, President & Director
Mr. Michael S. Richman MSBA
Co-Founder, CEO, President & Director
Mr. Michael S. Richman MSBA
Headquarters
Beltsville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NextCure Inc (NXTC) stood at $ 81 Mln as on 31-Dec-24
The share price of NextCure Inc (NXTC) is $0.46 (NASDAQ) as of 25-Apr-2025 16:00 EDT. NextCure Inc (NXTC) has given a return of -53.85% in the last 3 years.
NextCure Inc (NXTC) has a market capitalisation of $ 10 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of NextCure Inc (NXTC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NextCure Inc (NXTC) and enter the required number of quantities and click on buy to purchase the shares of NextCure Inc (NXTC).
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Address: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705
The CEO & director of Mr. Michael S. Richman MSBA. is NextCure Inc (NXTC), and CFO & Sr. VP is Mr. Michael S. Richman MSBA.
There is no promoter pledging in NextCure Inc (NXTC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| NextCure Inc (NXTC) | Ratios |
|---|---|
|
Return on equity(%)
|
-61.87
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NextCure Inc (NXTC) was $0 Mln.
$0.04
(
